Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

Trends in Pediatric Inpatient Sildenafil Use in the US, 2004 - 2013

Delphine Yung


S. Kristen Sexson Tejtel


Reviews

  Sign in to add a review

0 comments
Leave a Comment

Conference: 2014 International PHA Conference and Scientific Sessions

Release Date: 06.21.2014

Presentation Type: Abstracts

File Download: 2014 Conference Abstract - Delphine Yung

Download Adobe Acrobat

Since sildenafil became commercially available in 1998 and approved for adult pulmonary arterial hypertension (PAH) in 2005, reports of pediatric sildenafil use have increased. However, a black-box FDA warning was given in the summer of 2012 based on results of a placebo-controlled trial in children ages 1-17. We sought to understand sildenafil use in hospitalized children over time.

Background: Since sildenafil became commercially available in 1998 and approved for adult pulmonary arterial hypertension (PAH) in 2005, reports of pediatric sildenafil use have increased. However, a black-box FDA warning was given in the summer of 2012 based on results of a placebo-controlled trial in children ages 1-17. We sought to understand sildenafil use in hospitalized children over time.

Methods: The Pediatric Health Information System (PHIS) database was queried between January 2004 and June 2013 for sildenafil use in hospitalized patients with demographic, primary diagnosis and clinical data.

Results: There were 23,164 hospitalized children who received at least one dose of sildenafil.

Table 1. Clinical Data Number %
[Primary Diagnosis]   
- Congenital Heart Disease
5589 (24)
- Pulmonology hypertension
1624 (7)
- Pneumonia (baterial or viral)
1629 (7)
Prematurity or RDS 888 (4)
Gender, Male 12133 (52)
Length of stay 7 days or less 9816 (42)
Mechanical ventilation 13122 (57)
ECMO 1431 (6)
Readmission within 1 year 9748 (55)

 

Figure 1. Number of patients with sildenafil use by age and eyar, plus mortality. The first use was reported in 2004. 

Delphine Yung Abstract - 2014 Conference

 

Conclusion: After the FDA warning against sildenafil use in children in 2012 there has been decrease in the use of sildenafil use in all age groups and an asscociated decrease in mortality.